Offering Support and Electronic Resources for Care Partners of Those With Multiple Sclerosis

Sponsor
Case Western Reserve University (Other)
Overall Status
Completed
CT.gov ID
NCT04662008
Collaborator
(none)
151
1
2
11.9
12.7

Study Details

Study Description

Brief Summary

This study is an enhancement of the Fatigue Management Programs for People with MS study (NCT03550170). The purpose of this randomized clinical trial is to test the effectiveness of two interventions delivered remotely to support unpaid caregivers (UC) of people with multiple sclerosis (MS). We hypothesize that a high resource intervention will be significantly better than a lower resource intervention in terms of the primary outcome (UC anxiety, depression, and stress) and secondary outcome (COVID specific anxiety).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Tele-coaching
  • Behavioral: Website
N/A

Detailed Description

UCs are often caring for persons with chronic disabling conditions, who are at higher risk for severe COVID-19 illness. This presents incredibly stressful situations for UCs, which can result in depression, anxiety, and worse health outcomes both for them and their care recipients. Until a vaccine becomes available, these demands will force UCs to provide more support, whether in-person or remotely, for persons with MS. The aim of this study is to compare 2 modes of supporting UCs of people with MS. We will compare the effectiveness of a high resource highly tailored intervention that includes tele-coaching intervention (delivered via videoconference or phone) + web site information to a low-resource web-site only intervention. Our primary outcomes are UC anxiety, depression, and stress (DASS-42 scale) and a secondary outcome is COVID specific anxiety (CAS scale). These 2 interventions were selected because they will inform administrators and clinicians on whether a resource-intensive or a low-resource intervention is needed to yield meaningful outcomes. The comparison will also help UC decide how they should spend their limited time. These interventions are relevant to UCs of people with MS because of their need for tailored information provided in flexible ways to promote learning and support.

Study Design

Study Type:
Interventional
Actual Enrollment :
151 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
CLOSER_MS: Communicating With Local or Distance Caregivers Offering Support and Electronic Resources
Actual Study Start Date :
Mar 10, 2021
Actual Primary Completion Date :
Mar 7, 2022
Actual Study Completion Date :
Mar 7, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: High resource tailored intervention

Tele-coaching arm

Behavioral: Tele-coaching
This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.

Behavioral: Website
This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.

Active Comparator: Low-resource web-only intervention

Website arm

Behavioral: Website
This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.

Outcome Measures

Primary Outcome Measures

  1. anxiety, depression, and stress (DASS-42) [Each subject will be given the assessments at 3 points during the study: baseline, 6 weeks, and 12 weeks]

    Change from baseline in anxiety, depression, and stress levels. Each of the three DASS scales contains 14 items. Using a 4-point Likert scale, scores range from 0- 42 for each scale. Higher scores indicate more depression, anxiety, and stress.

Secondary Outcome Measures

  1. COVID specific anxiety (CAS scale) [Each subject will be given the assessments at 3 points during the study: baseline, 6 weeks, and 12 weeks]

    Change from baseline in COVID specific anxiety. Using a 5-point scale, from 0 (not at all) to 4 (nearly every day), total score ranges from 0-20 while individual items range from 0-4. Higher scores indicate higher anxiety.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. An adult family member or friend (18 years of age or older) of a person with MS

  2. Self-identified as an unpaid caregiver for person with MS

  3. Access to internet

  4. Capable of providing informed consent in English

Exclusion Criteria:
  1. Under age 18

  2. Cannot speak English

  3. Unable to provide consent

  4. No access to the internet

Contacts and Locations

Locations

Site City State Country Postal Code
1 Case Western Reserve University Cleveland Ohio United States 44124

Sponsors and Collaborators

  • Case Western Reserve University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Case Western Reserve University
ClinicalTrials.gov Identifier:
NCT04662008
Other Study ID Numbers:
  • MS-1610-37015 enhancement
First Posted:
Dec 10, 2020
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022